Cite
HARVARD Citation
Yang, D. et al. (2022). Analysis of US Food and Drug Administration Oncology Approvals on the Characterization of Hepatic Impairment Effect and Dosing Recommendations. Clinical pharmacology & therapeutics. 112 (4), pp. 782-790. [Online].